Acorda’s CVT-301 for Parkinson’s ‘Off’ Periods Shows Promising Results in Preclinical Studies


(October 19, 2016) - CVT-301, an inhalable drug under development by Acorda Therapeutics to treat Parkinson’s symptoms during “off” periods when currently available drugs don’t adequately work, showed promising results in preclinical Phase 1 and 2 studies. Read more

Click for a printer friendly version

Back to top